Ionizable Lipid — Proprietary Patented Structure
The core functional component of an LNP: a pH-responsive ionizable lipid with a proprietary, independently patented structure — not an SM-102 / ALC-0315 / MC3 analogue. China / US / EU patents; CDE excipient registration and FDA DMF filing completed. ISO 9001 / 13485, ICH-Q7A production.
Ionizable Lipid — ALC-0315 Type (Research Grade)
Research-grade ionizable lipid of the ALC-0315 type — the second-generation structure used in the Pfizer–BioNTech COVID-19 vaccine and the reference formulation for a large share of published LNP research. pH-responsive, ≥98% purity, −20 °C cold chain. Research use only.
Ionizable Lipid — MC3 Type (D-Lin-MC3-DMA, Research Grade)
Research-grade ionizable lipid of the MC3 (D-Lin-MC3-DMA) type — the first-generation benchmark lipid of Onpattro, the first approved siRNA drug. pKa ≈ 6.44, ≥98% purity, −20 °C cold chain. Research use only.
Vaccinia Capping Enzyme (mRNA 5' Capping, Cap 0/Cap 1)
Recombinant vaccinia capping enzyme (D1-D12) with three-in-one activity for enzymatic mRNA 5' capping — ~100% Cap 0 in 1 hour, upgradeable to Cap 1. Low endotoxin, low host residuals, RUO.
Need specs, pricing or lead time?
Tell us what you're working on and we'll reply with a clear quote — usually within one business day.